A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
1. To evaluate the safety and tolerability of xy0206 as single drug in the treatment of
relapsed / refractory AML;
2. Evaluate the dose limited toxicity (DLT) and maximum tolerable dose (MTD) of xy0206 as
single drug in the treatment of relapsed / refractory AML subjects.
3. To evaluate the pharmacokinetic (PK), pharmacokinetic (PD) characteristics and PK / PD
correlation of xy0206 as single drug treatment in relapsed / refractory AML subjects;
4. To evaluate the primary efficacy of xy0206 as single drug in the treatment of relapsed /
refractory AML patients;
5. To evaluate biomarkers of xy0206 as single drug treatment for relapsed / refractory AML
subjects.